Compound hub · CJC-1295
CJC-1295 side effects: what studies and regulators have recorded
CJC-1295 has no established long-term safety record. Two short trials of the DAC form found no serious harmful reactions, but they did record flushing and other unwanted effects. No paper checked gives a flushing rate for CJC-1295 and ipamorelin used together. The public summary of the separate ipamorelin trial gives no count for flushing on its own.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
Every medicine you have taken came with a leaflet of side effects. That leaflet exists because trials were large enough, and long enough, to count what went wrong. Your body is a fine detector of trouble, but a handful of stories is not a count. CJC-1295 has barely been counted. This page is part of the CJC-1295 hub. It sets out what the few human studies recorded, what regulators have written, and what the sources reviewed did not measure.
The answers below keep four things apart that people often mix up online: a study result, a regulator's statement, a review's summary and a guess. Each section lists where its facts come from. The companion page on what studies found CJC-1295 does covers the hormone results.
Key facts
| Compound | CJC-1295, a lab-made relative (analogue) of growth hormone-releasing hormone (GHRH). |
|---|---|
| Published human safety studies | Two randomised trials in healthy adults aged 21 to 61, lasting 28 and 49 days. The abstract gives no head count and no event counts. Source: Teichman et al., 2006. |
| Serious adverse reactions in those trials | None reported by the authors (Teichman et al., 2006) |
| Registered phase 2 trial | NCT00267527, HIV visceral obesity, listed enrolment 120, terminated, no results posted. Source: Checked 14 October 2026. |
| Long-term human safety data | None published, according to a 2026 review. A review's statement, not a trial result (Dominikowski et al., 2026). |
| Form without DAC | The same review found no peer-reviewed human studies of it. That does not show whether side effects were recorded elsewhere. Source: Dominikowski et al., 2026. |
| FDA compounding page | Safety-risk entry on the withdrawn-nominations list. Page current as of 22 April 2026 (FDA page). |
| Approval as a medicine, 2026 | Not approved by FDA or EMA, according to the same review. Source: Dominikowski et al., 2026. An openFDA search of Drugs@FDA on 14 October 2026 found no CJC-1295 application (search). |
What are the side effects of CJC-1295?
Only two small human trials have looked for side effects of CJC-1295. Both were randomised and double-blind. That means chance decided who got the peptide and who got a placebo (a dummy treatment), and nobody knew which was which. The trials ran for 28 and 49 days in healthy adults aged 21 to 61. The authors reported no serious harmful reactions. They concluded the peptide was safe and relatively well tolerated. But the short public summary, called the abstract, does not say how many people took part. It names no specific mild effects and gives no counts of events.
The full paper says more than the abstract. It records flushing, headache and other unwanted events in the healthy adults. The flushing section below uses that fuller safety text. Where this page says "the abstract", it means only the shorter summary.
A second human study, by Ionescu and Frohman, followed healthy men for one week after a single exposure. It reported hormone results, not a table of side effects. Its abstract also gives no head count.
Some reviews list side effects for the whole family of peptides that act on the growth hormone system, not for CJC-1295 alone. A 2026 narrative review (an expert summary of other studies, not a new experiment) lists rises in two hormones, prolactin and cortisol. It also lists appetite change, blood-sugar change, fluid retention, muscle and joint aches, and reactions at the spot where the drug was given. This is a list for the whole group. It is not a measurement for CJC-1295.
The review links the prolactin and cortisol rises to older peptides that copy a natural hormone called ghrelin, such as GHRP-2, GHRP-6 and hexarelin. It describes ipamorelin and the GHRH analogues as sparing those hormones. Again, that is the review's reading of other work. A list like this shows what researchers watch for.
Evidence limits
Is CJC-1295 safe?
No study found for this page shows CJC-1295 is safe in the way an approved medicine is shown to be safe. That takes large trials that run for a long time. The human work found is two short trials in healthy adults aged 21 to 61. Their abstract reports no serious harmful reactions, but gives no head count and no event counts. One phase 2 trial, a mid-stage test in patients, was registered with a listed enrolment of 120. It was terminated, and no results are posted (ClinicalTrials.gov NCT00267527, checked 14 October 2026). A 2026 review says no long-term human safety data exist for the DAC form.
The registry record gives no reason for stopping the trial, so this page does not guess one. The trial was planned as a multicentre, randomised, placebo-controlled, double-blind phase 2 study. It was meant to run for 12 weeks, plus 6 weeks of follow-up, in HIV-infected adults with visceral obesity (extra fat stored deep in the belly, around the organs). Its status was last verified in October 2006.
A Europe PMC search for CJC-1295 on 14 October 2026 returned 59 records. None of their titles is a results paper from this trial.
A 2026 review of peptides in sports medicine makes a wider point. It says many unapproved peptides have favourable results in animals, but rigorous human safety data on them are scarce, and serious harm is possible. That is a statement about the whole group, not a finding on CJC-1295. Nobody treats a medicine as safe just because harm has not been proven yet.
What does the FDA say about CJC-1295 safety?
The US Food and Drug Administration (FDA) lists serious adverse events, meaning serious harmful medical events, associated with CJC-1295. They include a faster heart rate and a systemic vasodilatory reaction, where blood vessels widen throughout the body. The FDA adds that clinical data are limited. Its page does not name the study or report behind these events. It also says compounded drugs containing CJC-1295 may carry a risk of immunogenicity for certain routes. Compounded drugs are made up by a pharmacy, not a drug company. That means the body may make antibodies against the peptide. The page also flags problems with impurities and with confirming exactly what the substance is.
The source is the FDA page Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 22 April 2026.
Read the page closely and one more limit appears. CJC-1295 is on the page's list of substances whose compounding nominations were withdrawn. It is not on the category 2 table of active safety concerns.
The same page puts ipamorelin acetate in category 2 for outsourcing facilities. These are a type of compounding business covered by section 503B of the US Federal Food, Drug, and Cosmetic Act. It was added on 29 September 2023. The FDA gives two reasons. Ipamorelin contains unnatural amino acids, which make it harder to confirm what the substance is. And a published study found serious adverse events, including death, when ipamorelin was used for gastric motility. That means how the gut moves food along.
The FDA page does not name that study in its text, but its linked reference is Beck et al. (2014), PubMed 25331030. This page keeps the FDA's report apart from that paper's own results, which were checked separately. It does not guess a death count or cause from the abstract. The agency also says it found no safety information for certain other routes.
This is a US compounding rule, not Australian law. The Australian law guide covers the Poisons Standard.
What are the side effects of CJC-1295 with DAC?
CJC-1295 with DAC is the only form with published human safety data found for this page. DAC stands for drug affinity complex. It is a chemical hook that ties the peptide to albumin, a protein carried in the blood. In two trials of healthy adults aged 21 to 61, lasting 28 and 49 days, the authors reported no serious harmful reactions. The estimated half-life, the time for half of it to clear, was 5.8 to 8.1 days. Average levels of IGF-I, a marker driven by growth hormone, stayed above starting levels for up to 28 days after repeated exposures. The abstract gives no head count and no event counts.
A long half-life changes what researchers worry about. Growth hormone makes the liver produce IGF-I (insulin-like growth factor I), a growth signal. A 2026 narrative review calls IGF-I that stays high for a long time the central long-term concern for the whole class.
The same review names mitogenic effects, meaning effects that could encourage cell growth. It calls them biologically plausible but unproven. It bases this on reasoning about the class, not on CJC-1295 trial data.
Tesamorelin is an approved relative. Its US label says the effects of IGF-1 staying high for a long time are unknown (Egrifta SV label, DailyMed updated 29 July 2026). No study found measured these questions for CJC-1295 over months or years.
What DAC is and is not is covered separately. The CJC-1295 with DAC versus without DAC guide sets out how the two forms differ in structure and in the published record.
What are the side effects of CJC-1295 without DAC?
A 2026 review found no peer-reviewed human studies of CJC-1295 without DAC. That does not prove side effects were never recorded somewhere else. The review puts this form in the lowest of four evidence tiers. That tier rests only on lab and animal results stretched to people, and on users' personal stories. The tier is a label for the evidence, not a safety finding. The review adds that most claims about this form come from related compounds, such as sermorelin, the unmodified fragment, and from non-academic sources. So the safety of CJC-1295 without DAC is unknown.
The human data from the 2006 trials belong to the DAC form. They cannot be borrowed for the shorter peptide. The two molecules differ in length, in published evidence and in registry record.
The form comparison guide reports a PubMed search on 3 October 2026. It found no measured human half-life for the peptide without DAC.
What are the side effects of CJC-1295 with ipamorelin?
No published human safety study of CJC-1295 and ipamorelin together was found. A Europe PMC search on 14 October 2026 found 22 records that mention both names. Judging by their titles, none reports a controlled human trial of the pair. They are reviews, preprints, doping-test papers, product-quality checks and surveys. A 2026 review calls controlled evidence for the pairing limited. Ipamorelin alone has one phase 2 trial. It was a small proof-of-concept study that enrolled 117 patients after bowel surgery, with 114 analysed for safety. Some unwanted event that began during treatment happened in 87.5% of the ipamorelin group and 94.8% of the placebo group.
The trial's authors note that it enrolled patients with a broad range of conditions. They concluded ipamorelin was well tolerated over its short hospital treatment period. It did not differ from placebo on the main result the trial was testing.
That was a hospital trial in patients after surgery, with a different purpose. It says little about any other group, or about two peptides together. The trial is registered as NCT00672074. A second trial for ileus (a gut that stops moving after surgery), NCT01280344, lists 320 people and no posted results. Source: Checked 14 October 2026.
In awake pigs, two stress-related hormones, ACTH and cortisol, did not differ much after ipamorelin from after GHRH. The older peptides GHRP-6 and GHRP-2 did raise them. This animal result describes which hormones a peptide affects, not safety in people.
What do CJC-1295 and ipamorelin studies record about flushing?
Flushing has been recorded with CJC-1295 with DAC. Flushing means the skin turns red and feels warm. The sources checked do not give a flushing rate for CJC-1295 and ipamorelin together. In the healthy-adult trials of CJC-1295, the researchers described flushing, warmth and brief low blood pressure. The paper calls these systemic vasodilatory reactions: blood vessels widening across the body. The ipamorelin study after bowel surgery counted unwanted events. But its public abstract gives no result for flushing on its own. A missing entry is not evidence that flushing never happened.
In the repeat-exposure CJC-1295 study, flushing began within 30 minutes and ended within 1–2 hours. Those observations belong to the DAC form studied on its own. The CJC-1295 form comparison explains why that difference matters.
The ipamorelin safety record needs its own evidence. On 16 October 2026, web searches of PubMed and Europe PMC for both compound names plus flushing found no controlled human study of the pair. A limited search like that does not prove that no report exists.
Personal stories of a hot flush cannot give a rate. A rate needs a defined group, a comparison group and a checked compound identity.
What are the long-term side effects of CJC-1295?
The long-term side effects of CJC-1295 are unknown, because no long-term human study was found. The longest human trials found ran for 28 and 49 days, in healthy adults. A 2026 review says no long-term safety data are available for the DAC form. Sport Integrity Australia makes a wider point on its peptides page, read on 14 October 2026. It says few studies look at the long-term health effects of unapproved peptides, so their possible side effects remain largely unknown. It adds that most toxicity research, meaning tests for harm, has been done in animals.
Compare that with an approved relative. The US label for tesamorelin rests on trials in patients. Even so, it says long-term heart and blood-vessel safety has not been established (Egrifta SV label).
The two CJC-1295 trials followed healthy adults for 28 and 49 days. Trials that short cannot establish long-term safety.

What side effects does the label of tesamorelin, an approved GHRH analogue, list?
Tesamorelin (Egrifta) is a different GHRH analogue. It is approved in the United States to reduce excess belly fat in HIV-infected adults with lipodystrophy. That is a condition where body fat builds up or is lost in unusual places. Its label lists the most common adverse reactions among 543 patients who received it in the 26-week placebo-controlled part of its trials. They were allergy-type reactions, reactions linked to fluid build-up, high blood sugar and reactions where the drug was given. These entries describe tesamorelin in patients with HIV. They are not measurements for CJC-1295.
The label's fluid-related reactions are joint pain, pain in the arms or legs, swelling in the limbs and carpal tunnel syndrome. Carpal tunnel syndrome is a squeezed nerve in the wrist (Egrifta SV label).
The label's warnings cover neoplasms (new growths such as tumours), raised IGF-1, fluid retention, glucose intolerance and hypersensitivity. None of this makes any research material equal to the approved medicine.
The label gives counts that CJC-1295 lacks. Its glucose-intolerance warning, about trouble handling blood sugar, comes from the same trials. HbA1c is a long-term blood-sugar test. The passage read does not say how many people its HbA1c figures are based on. So this page does not repeat them (Egrifta WR label).
In the main trial of 412 adults with HIV over 26 weeks, adverse events did not differ significantly between the groups. More tesamorelin patients did withdraw because of one. That result belongs to that medicine in that group of patients.
Why mention a different molecule? Because it shows the shape of the missing evidence. A regulated growth hormone-releasing analogue has trial tables and warnings. CJC-1295 has two short trials in the records read and a terminated one.
What adverse events has the TGA recorded for unapproved peptide products?
The Therapeutic Goods Administration (TGA), Australia's medicines regulator, issued a safety advisory on 13 April 2026. It lists reports linked to unapproved peptide products as a group. They include severe allergic reactions needing adrenaline and hospital care. They also include systemic inflammatory response syndrome, which is body-wide inflammation. Others are allergy-type symptoms across the body, trouble sleeping, blurred vision, extreme tiredness, flu-like illness, joint pain and injuries to muscles and bones. The advisory names CJC-1295 as an example of an unapproved peptide product. It does not link any single report to CJC-1295.
Because the events are listed for the group, they show what regulators see in practice. They do not show how often any one peptide causes them.
The TGA also says unapproved peptide products have not been assessed for safety, quality or effectiveness. It says important facts are unknown, including what side effects they may cause and what the products contain. It adds that a research-use-only label does not make supply lawful and does not change a product's regulatory status. The Australian law guide sets out the Poisons Standard entries for CJC-1295.
What do anti-doping bodies say about CJC-1295?
The World Anti-Doping Agency (WADA) keeps a list of substances banned in sport. Its Prohibited List 2026, in effect from 1 January 2026, names CJC-1295 under section S2.2.4. It is given as an example of a growth hormone-releasing hormone analogue, a class prohibited at all times. Sport Integrity Australia also lists CJC-1295 among common unapproved peptides prohibited in sport, on its peptides page, read 14 October 2026. Both documents record sport status. Neither is a safety trial, and neither reports an adverse-event rate for CJC-1295.
The Sport Integrity Australia page also says unapproved peptides do not pass the same quality control as approved medicines. So their purity and make-up can vary widely, which could lead to serious harm. The page points to the TGA's reported effects: severe allergic reactions, inflammation, blurred vision, extreme tiredness and musculoskeletal injuries. Those are the TGA's reports for the whole group, not a CJC-1295 finding.
Is research-use CJC-1295 the material the studies tested?
No. The studies above tested the sponsor's own trial product. It was given to enrolled people under clinical-trial conditions. Research-use reference material is a laboratory compound. Its published safety record is the record described on this page. None of that record describes any material outside those trials. A certificate of analysis is a lab report on one sample from one batch, called a lot. So it cannot carry a trial's safety record over to another product. Research material is not a medicine. It is not a substitute for one, and it is not for human or animal use.
The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial, with the split between the two compounds unstated. Most of the human safety record above concerns the DAC form. So it is background for naming and method, not direct evidence about the No DAC peptide. The CJC-1295 and ipamorelin research guide covers the compound families.
Comparison
Published safety records as read on 14 October 2026. Tesamorelin is a different molecule, shown only for contrast. This is not a comparison of medicines.
| Record | CJC-1295 with DAC | CJC-1295 without DAC | Ipamorelin | Tesamorelin (approved, different molecule) |
|---|---|---|---|---|
| Human trials published | Two randomised trials in healthy adults aged 21 to 61, lasting 28 and 49 days. Abstract gives no head counts or event counts (Teichman et al., 2006). | None found by a 2026 review. That does not show whether effects were recorded elsewhere. Source: Dominikowski et al., 2026. | A blood-level study of eight healthy men at each of five levels. Source: Gobburu et al., 1999. One small phase 2 trial of 117 patients after bowel surgery, 114 analysed. Source: Beck et al., 2014. | One main trial of 412 adults with HIV and belly fat over 26 weeks. Source: Falutz et al., 2007. The label also reports follow-up to 52 weeks in patients who completed. |
| Any unwanted event during treatment | No event counts in the abstract (Teichman et al., 2006) | No data found | 87.5% of the ipamorelin group and 94.8% of the placebo group, among 114 analysed bowel-surgery patients with a broad range of conditions. Source: Beck et al., 2014. | No single rate given here. The label's table covers 543 patients who received tesamorelin in the 26-week placebo-controlled phase. Source: Egrifta SV label, 2026. |
| Serious adverse events reported by study authors | None reported in healthy adults aged 21 to 61. Abstract gives no head counts or event counts (Teichman et al., 2006). | No data found | The abstract gives no serious-event count, so this page gives no rate. Source: Beck et al., 2014. | No serious-event rate checked for this page. Adverse events did not differ much between groups. More tesamorelin patients left because of one (Falutz et al., 2007). |
| Regulator statements (not rates, and no cause inferred) | FDA lists serious adverse events associated with CJC-1295 and says clinical data are limited, without naming a source (FDA). | No separate FDA entry; the entry names CJC-1295 only | FDA cites a published study, linked as Beck et al. (2014), that identified serious adverse events including death in ipamorelin used for gastric motility. No death count or cause is inferred here. | Label warnings: neoplasms, IGF-1 rise, fluid retention, glucose intolerance, hypersensitivity. Source: Egrifta SV label, 2026. |
| Long-term human safety data | None found (Dominikowski et al., 2026) | None found | Not located. The phase 2 treatment period was short, in days. Source: Beck et al., 2014. | Label: long-term cardiovascular safety not established (Egrifta SV label, 2026). |
| FDA compounding page, current as of 22 April 2026 | Named on the withdrawn-nominations list with a safety-risk entry. | Same entry names CJC-1295 only | Ipamorelin acetate in category 2 (503B), added 29 September 2023. | Approved medicine, not a compounding bulk substance |
FAQ
Does a hot flush establish how CJC-1295 and ipamorelin work together?
No. A hot flush cannot show a combined effect. The 2006 trials recorded flushing with CJC-1295 with DAC on its own. That result cannot identify the cause of a personal reaction to a mixed or unverified product.
Did the ipamorelin trial report a flushing rate?
No. The public abstract of the 2014 bowel-surgery trial reports overall unwanted events but no separate flushing count. Flushing frequency cannot be worked out from that summary, and no such rate is established for the pair.
Is CJC-1295/ipamorelin safe?
No safety conclusion can be drawn. No published human study of the two together was found, and a 2026 review calls controlled evidence for the pairing limited.
What are the common side effects of CJC-1295?
No common-side-effect rate was found in the abstracts read. The two human trials in healthy adults aged 21 to 61 report no serious adverse reactions. Their abstracts give no head count and no event rates.
What are the negative side effects of CJC-1295?
The FDA lists serious adverse events including a faster heart rate and a systemic vasodilatory reaction, without naming its source. Source: Page current as of 22 April 2026. The two human trials in healthy adults aged 21 to 61 report none that were serious, with no head counts or event counts in the abstract.
Is CJC a safe peptide?
Safety has not been established. The human data found are two short trials in healthy adults with no head count in the abstract. One terminated phase 2 trial has no posted results (ClinicalTrials.gov NCT00267527), and no long-term data were found.
What are the long-term side effects of CJC-1295 and ipamorelin?
Unknown. The longest published CJC-1295 human trial found lasted 49 days, in healthy adults with no head count in the abstract. The published ipamorelin phase 2 trial had a short treatment period, in patients after bowel surgery.
Does the TGA say CJC-1295 is safe?
No. The TGA's advisory of 13 April 2026 names CJC-1295 as an example of an unapproved peptide product. It says such products have not been assessed for safety, quality or effectiveness.
More in this hub
Citations
8 sourcesTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
doi:10.1210/jc.2005-1536Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
doi:10.1210/jc.2006-1702Dominikowski A, Rękoś Z, Olejarz M, et al. Frontiers in Endocrinology. 2026;17:1822475.
doi:10.3389/fendo.2026.1822475Mendias CL, Awan TM. Sports Medicine. 2026;56(8):1921-1935.
doi:10.1007/s40279-026-02437-0Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
doi:10.1007/s00384-014-2030-8Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology. 1998;139:552-561.
doi:10.1530/eje.0.1390552Falutz J, Allas S, Blot K, et al. New England Journal of Medicine. 2007;357(23):2359-2370.
doi:10.1056/nejmoa072375Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical Research. 1999;16(9):1412-1416.
doi:10.1023/a:1018955126402
Continue
CJC-1295 (No DAC) & ipamorelin reference materialResearch use only: not for human or animal use.
Read the CJC-1295 and ipamorelin research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
